Herpesvirus Infections in Transplant Recipients: Current Challenges in the Clinical Management of Cytomegalovirus and Epstein-Barr Virus Infections

Raymund R Razonable, Carlos V. Paya

Research output: Contribution to journalArticle

115 Citations (Scopus)

Abstract

Herpesvirus infections are common causes of morbidity and mortality in solid organ and haematopoietic stem cell transplant recipients. Significant scientific breakthroughs have reduced the incidence of herpesvirus infections during the early post-transplant period, but herpesvirus infections continue to impact significantly on the outcome of transplantation. Widespread and prolonged use of antiviral drugs has not eliminated the risk of cytomegalovirus (CMV) disease, but has changed its natural course by delaying its onset. Moreover, there is now increased recognition of ganciclovir (and other antiviral drug)-resistant CMV infections. By contrast, optimal preventive and treatment strategies for Epstein-Barr virus-related post-transplant lymphoproliferative disorders (PTLD) remain elusive. Recent experimental and clinical data, however, demonstrate a promising role for immunotherapy in preventing and treating PTLD. This review highlights the current challenges in managing CMV and Epstein-Barr virus infections in transplant patients.

Original languageEnglish (US)
Pages (from-to)60-65
Number of pages6
JournalHerpes
Volume10
Issue number3
StatePublished - Dec 2003

Fingerprint

Herpesviridae Infections
Epstein-Barr Virus Infections
Cytomegalovirus
Transplants
Lymphoproliferative Disorders
Antiviral Agents
Ganciclovir
Cytomegalovirus Infections
Hematopoietic Stem Cells
Human Herpesvirus 4
Immunotherapy
Transplantation
Transplant Recipients
Morbidity
Mortality
Incidence

Keywords

  • Cytomegalovirus (CMV)
  • Epstein-Barr virus (EBV)
  • Ganciclovir-resistant cytomegalovirus
  • Immunotherapy
  • Late-onset CMV disease
  • Post-transplantation lymphoproliferative disease
  • Transplantation

ASJC Scopus subject areas

  • Virology
  • Dermatology

Cite this

@article{7ca5ea399d3b4c48b49e9f5f3d3c72e6,
title = "Herpesvirus Infections in Transplant Recipients: Current Challenges in the Clinical Management of Cytomegalovirus and Epstein-Barr Virus Infections",
abstract = "Herpesvirus infections are common causes of morbidity and mortality in solid organ and haematopoietic stem cell transplant recipients. Significant scientific breakthroughs have reduced the incidence of herpesvirus infections during the early post-transplant period, but herpesvirus infections continue to impact significantly on the outcome of transplantation. Widespread and prolonged use of antiviral drugs has not eliminated the risk of cytomegalovirus (CMV) disease, but has changed its natural course by delaying its onset. Moreover, there is now increased recognition of ganciclovir (and other antiviral drug)-resistant CMV infections. By contrast, optimal preventive and treatment strategies for Epstein-Barr virus-related post-transplant lymphoproliferative disorders (PTLD) remain elusive. Recent experimental and clinical data, however, demonstrate a promising role for immunotherapy in preventing and treating PTLD. This review highlights the current challenges in managing CMV and Epstein-Barr virus infections in transplant patients.",
keywords = "Cytomegalovirus (CMV), Epstein-Barr virus (EBV), Ganciclovir-resistant cytomegalovirus, Immunotherapy, Late-onset CMV disease, Post-transplantation lymphoproliferative disease, Transplantation",
author = "Razonable, {Raymund R} and Paya, {Carlos V.}",
year = "2003",
month = "12",
language = "English (US)",
volume = "10",
pages = "60--65",
journal = "Herpes",
issn = "0969-7667",
publisher = "Cambridge Medical Publications",
number = "3",

}

TY - JOUR

T1 - Herpesvirus Infections in Transplant Recipients

T2 - Current Challenges in the Clinical Management of Cytomegalovirus and Epstein-Barr Virus Infections

AU - Razonable, Raymund R

AU - Paya, Carlos V.

PY - 2003/12

Y1 - 2003/12

N2 - Herpesvirus infections are common causes of morbidity and mortality in solid organ and haematopoietic stem cell transplant recipients. Significant scientific breakthroughs have reduced the incidence of herpesvirus infections during the early post-transplant period, but herpesvirus infections continue to impact significantly on the outcome of transplantation. Widespread and prolonged use of antiviral drugs has not eliminated the risk of cytomegalovirus (CMV) disease, but has changed its natural course by delaying its onset. Moreover, there is now increased recognition of ganciclovir (and other antiviral drug)-resistant CMV infections. By contrast, optimal preventive and treatment strategies for Epstein-Barr virus-related post-transplant lymphoproliferative disorders (PTLD) remain elusive. Recent experimental and clinical data, however, demonstrate a promising role for immunotherapy in preventing and treating PTLD. This review highlights the current challenges in managing CMV and Epstein-Barr virus infections in transplant patients.

AB - Herpesvirus infections are common causes of morbidity and mortality in solid organ and haematopoietic stem cell transplant recipients. Significant scientific breakthroughs have reduced the incidence of herpesvirus infections during the early post-transplant period, but herpesvirus infections continue to impact significantly on the outcome of transplantation. Widespread and prolonged use of antiviral drugs has not eliminated the risk of cytomegalovirus (CMV) disease, but has changed its natural course by delaying its onset. Moreover, there is now increased recognition of ganciclovir (and other antiviral drug)-resistant CMV infections. By contrast, optimal preventive and treatment strategies for Epstein-Barr virus-related post-transplant lymphoproliferative disorders (PTLD) remain elusive. Recent experimental and clinical data, however, demonstrate a promising role for immunotherapy in preventing and treating PTLD. This review highlights the current challenges in managing CMV and Epstein-Barr virus infections in transplant patients.

KW - Cytomegalovirus (CMV)

KW - Epstein-Barr virus (EBV)

KW - Ganciclovir-resistant cytomegalovirus

KW - Immunotherapy

KW - Late-onset CMV disease

KW - Post-transplantation lymphoproliferative disease

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=0347285458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347285458&partnerID=8YFLogxK

M3 - Article

C2 - 14759337

AN - SCOPUS:0347285458

VL - 10

SP - 60

EP - 65

JO - Herpes

JF - Herpes

SN - 0969-7667

IS - 3

ER -